香港股市 已收市

和黃醫藥 (0013.HK)

HKSE - HKSE 延遲價格。貨幣為 HKD。
加入追蹤清單
31.000-0.500 (-1.59%)
收市價: 04:08PM HKT
全螢幕
前收市價31.500
開市31.100
買盤31.000 x 無
賣出價31.050 x 無
今日波幅30.300 - 31.800
52 週波幅11.360 - 43.600
成交量3,418,645
平均成交量5,315,664
市值26.808B
Beta 值 (5 年,每月)0.89
市盈率 (最近 12 個月)1.97
每股盈利 (最近 12 個月)15.750
業績公佈日
遠期股息及收益率無 (無)
除息日
1 年預測目標價
  • Benzinga

    HUTCHMED Out Licenses Fruquintinib To Takeda Outside China

    HUTCHMED (China) Limited (NASDAQ: HCM) has entered into an exclusive license agreement with a subsidiary of Takeda Pharmaceutical Company Limited (NYSE: TAK) to further the global development, commercialization, and manufacture of fruquintinib outside China. Fruquintinib is orally administered and can potentially be used across subtypes of metastatic colorectal cancer (CRC), regardless of biomarker status. Results of the FRESCO-2 Phase 3 trial of fruquintinib in refractory metastatic CRC were pr

  • Benzinga

    Hutchmed-Lilly Partnered Gastric Cancer Drug Shows Mixed Results In Phase 3 Study

    HUTCHMED (China) Limited (NASDAQ: HCM) announced initial results from FRUTIGA Phase 3 trial of fruquintinib combined with paclitaxel in 703 Chinese patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. The trial met one of the primary endpoints of statistically significant improvement in progression-free survival (PFS), which is clinically meaningful. The other primary endpoint of overall survival (OS) was not statistically significant per the pre-specified statistica

  • Benzinga

    HUTCHMED Cancer Med Cuts Death Risk By 34% In Metastatic Colorectal Cancer

    HUTCHMED (China) Limited (NASDAQ: HCM) announced summary results of the 691-patient trial of fruquintinib. These results have been shared in an abstract of the upcoming presentation at the European Society for Medical Oncology Congress 2022. The MRCT FRESCO-2 study demonstrated that treatment with fruquintinib resulted in a statistically significant and clinically meaningful increase in the primary overall survival (OS) endpoint and key secondary progression-free survival (PFS) endpoint compared